Living definition
What is Tudriqev (vusolimogene oderparepvec) + Nivolumab?
Vaccines & Immunotherapy Bio, Health & Neuro
- As of
- 2026-08-20
- Revision
- 2026-08-17.1
- Method
- v1.3.0
Definition
The term, in context
AI-assisted draft · approved dataset
Tudriqev (vusolimogene oderparepvec) is an oncolytic herpes simplex virus therapy engineered to selectively replicate within tumor cells, causing direct lysis while expressing an immune-stimulating transgene intended to prime a broader anti-tumor immune response; it is designed for use alongside nivolumab, a PD-1 immune checkpoint inhibitor monoclonal antibody, combining direct tumor cell destruction with checkpoint blockade as a combination approach for treating melanoma.
Live readiness status
Status as of the current dateline
AI-assisted assembly · derived results
As of 2026-08-20, verified readiness is 90 (claimed 100, reported 97, gap 10) — Strong evidence strength; current signals suggest Proceed with caution.
The readiness fact belongs to the canonical Readiness Verdict for Tudriqev (vusolimogene oderparepvec) + Nivolumab.
Dataset approval
Human editorial release
pragma.vision editorial — standing authorization (operator dev@soft.house, 2026-07-17)
- Dataset
- 2026-08-17.1
- Hash
- sha256:0c37108a182f510fc8cf4d1dfc3a30339f2b59e62654201edea2f530a268707e
- Approved
- 2026-08-17